Butterfly Network, Inc. (BFLY) – Financial Prediction Report

BFLY – Increase Expected (21-day)

Butterfly Network, Inc. (BFLY) is a healthcare medical devices company specializing in handheld ultrasound solutions. Recent news highlights a co-development agreement with Midjourney Medical for full-body ultrasound scanners, with potential payments up to $74M over five years. The stock has rallied from a 52-week low of $1.32 to $8.90, near its high.

Despite overbought RSI and price above analyst target, strong product catalyst and revenue growth support a modest near-term increase.

Why This Matters

The Midjourney agreement could significantly boost revenue, while the company’s cash position and low debt provide stability. However, operational losses and high valuation require caution.

Key Insights

• Revenue growth of 18.96% YoY is positive, but net income remains negative (-$77M) with negative free cash flow.
• Gross margin (46.85%) is healthy, but operating margin (-88.53%) and net margin (-78.95%) show severe operational inefficiency.
• Cash & equivalents ($150M) and low debt/equity (0.10) provide a buffer, but high beta (2.20) adds volatility.
• Analyst consensus is strong_buy with an average price target of $7.06, below the current price of $8.90, limiting upside confidence.
• RSI (84.58) is overbought, indicating potential short-term pullback, but bullish news sentiment (67%) and product catalyst may sustain momentum.

Catalyst Analysis

The primary catalyst is the co-development agreement with Midjourney Medical, which includes up to $74M in payments over five years and potential for future generations of full-body scanners. This could drive 5%+ revenue growth. Additionally, the upcoming earnings report (estimated July 31, 2026) may provide further guidance. The 21-day horizon aligns with the earnings date and product commercialization timeline.

Signal Contradictions

Contradictions exist: (1) Bullish news sentiment (67% bullish) vs. overbought RSI (84.58) and price above analyst target ($8.90 vs $7.06). (2) Revenue growth (18.96%) vs. negative free cash flow and net income. (3) Strong buy consensus vs. deteriorating margins. These contradictions reduce confidence to a maximum of 6/10.

Margin & Efficiency Analysis

Gross margin (46.85%) is positive, but net margin (-78.95%) shows a 125.8pp gap, indicating high operating expenses relative to revenue. While revenue is growing, the gap is widening, suggesting operational inefficiency. This supports a bear case for sustained profitability and reduces confidence for an ‘increase’ prediction.

Practical Implications

• Bull Case: The Midjourney agreement could add $15M+ annual revenue, and the company’s cash position ($150M) supports R&D. The strong buy analyst consensus and product innovation (iQ3, Apollo AI chip) suggest long-term potential.
• Bear Case: Negative net income, negative free cash flow, and high operating expenses indicate ongoing losses. The stock is overbought (RSI 84.58) and trading above the average price target, limiting upside. Any delay in Midjourney commercialization could trigger a pullback.
• Sideways Risk: Moderate. The product theme (2 articles) and earnings theme (1 article) suggest high volatility around earnings and product updates. The overbought RSI increases risk of a short-term correction, but the catalyst may prevent a sharp decline.
• Confidence: 5/10 – Confidence is 5/10 due to multiple contradictions: bullish news vs. overbought RSI, price above target, and negative margins. The catalyst is real but not immediate (21-day horizon). Stale news is not an issue (all <7 days). The sentiment is 67% bullish, but the technical and fundamental risks cap confidence.

Prediction (21-day): increase

---

Analysis Metadata:

• News Collection: 2026-06-19
• Analysis Date: 2026-06-19
• Target Date: 2026-07-10

References:

• https://lasvegassun.com/news/2026/jun/18/butterfly-network-provides-commentary-on-midjourne/
• https://finance.yahoo.com/quote/BFLY/
• https://www.stocktitan.net/overview/BFLY/